Variables | OS(42/341) | PFS(63/341) | DMFS(49/341) | |||
---|---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
Gender (male vs female) | 1.053 (0.546–2.031) | 0.877 | 0.904 (0.518–1.578) | 0.723 | 0.737 (0.384–1.412) | 0.357 |
Age (≤50 vs >50) | 2.039 (1.092–3.807) | 0.025 | 1.512 (0.918–2.492) | 0.105 | 1.342 (0.761–2.367) | 0.310 |
Pathological type (WHO I-II vs WHO III) | 2.295 (0.361–14.583) | 0.379 | 1.961 (0.531–7.246) | 0.313 | 1.532 (0.420–5.588) | 0.518 |
T stage (T1-T2 vs T3-T4) | 1.329 (0.944–1.870) | 0.103 | 1.123 (0.866–1.457) | 0.382 | 1.129 (0.838–1.520) | 0.425 |
N stage (N0–1 vs N2–3) | 1.766 (1.186–2.630) | 0.005 | 1.378 (0.990–1.920) | 0.058 | 1.634 (1.117–2.391) | 0.011 |
Chemotherapy cycle (≤3 vs >3) | 2.381 (0.910–6.226) | 0.077 | 1.747 (0.830–3.676) | 0.142 | 1.808 (0.767–4.264) | 0.176 |
SUA level (≤327 vs >327) | 2.385 (1.208–4.707) | 0.012 | 1.658 (0.989–2.779) | 0.055 | 1.744 (0.964–3.156) | 0.066 |
Tumor response to IC (CR/PR vs SD/PD) | 1.915 (1.044–3.648) | 0.036 | 2.381 (1.408–3.816) | 0.001 | 2.764 (1.554–4.851) | 0.001 |